Platelet Gene Expression Scoring for Cardiovascular Risk Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current clinical methods are inadequate for routine assessment of platelet hyperreactivity and cardiovascular risk, limiting the identification of individuals at risk for significant cardiovascular events.
Innovation Solution
A method involving the determination of gene expression levels in a blood sample using a Platelet Reactivity Expression Score (PRESS) to assess platelet hyperreactivity, which calculates a z-scored predictive probability based on weighted expression values of specific genes, enabling the identification of individuals with platelet hyperreactivity and associated cardiovascular risk.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional platelet aggregation measures are used to assess platelet hyperreactivity, then diagnostic capability is improved, but technical barriers limit routine clinical assessment and implementation
Solution Approach 1:
The patent replaces complex mechanical and procedural platelet aggregation assessment systems with a molecular biology-based gene expression analysis system. By measuring mRNA expression levels of specific platelet genes using standardized laboratory techniques, the system achieves accurate platelet hyperreactivity assessment without the technical barriers of traditional aggregation methods.
Solution Approach 2:
The patent introduces gene expression profiles as an intermediary marker that reflects platelet hyperreactivity status. Instead of directly measuring platelet aggregation responses, the system uses mRNA expression levels of platelet-specific genes as a surrogate indicator, enabling indirect but accurate assessment of platelet reactivity states.
2Measurement precision
If comprehensive platelet transcriptome profiling is performed to identify novel aspects of platelet biology and diagnostic markers, then diagnostic accuracy is improved, but technical complexity and resource requirements increase
Solution Approach 1:
The patent extracts and focuses on specific platelet-related genes from the comprehensive transcriptome that are most relevant to platelet reactivity and cardiovascular risk. By selecting a targeted subset of genes rather than analyzing the entire transcriptome, the system achieves high diagnostic accuracy while reducing technical complexity and resource requirements.
Solution Approach 2:
The patent applies local quality by focusing analysis on specific platelet genes with known or suspected roles in platelet activation and thrombosis. Rather than uniform analysis of all transcripts, the system concentrates resources on measuring expression levels of key platelet genes, optimizing diagnostic performance for the specific purpose of assessing platelet hyperreactivity.
3Reliability
If gene expression analysis of multiple platelet genes is performed to calculate PRESS, then ability to identify individuals at cardiovascular risk is improved, but measurement and computational complexity increases
Solution Approach 1:
The patent transforms multiple gene expression measurements into a single composite parameter, the Platelet Reactivity Expression Score (PRESS). By converting individual gene expression levels into a unified scored metric through standardized scoring and summation, the system maintains high reliability in cardiovascular risk prediction while simplifying interpretation and clinical application.
Solution Approach 2:
The patent creates a composite diagnostic indicator (PRESS) by combining information from multiple platelet gene expressions. Similar to how composite materials combine different substances to achieve superior properties, the PRESS composite score integrates multiple gene expression parameters to provide a more reliable and comprehensive assessment of platelet hyperreactivity and cardiovascular risk than any single gene alone.
Data Source
AI summary
The present disclosure provides methods for determining whether a subject has platelet hyperreactivity. Further provided are methods for determining risk of developing a platelet-mediated cardiovascular and/or limb event in a subject, as well as determining whether a subject has a condition associated with platelet hyperreactivity. Still further provided are methods for preventing a cardiovascular and/or limb event in a subject in need thereof; treating or preventing a condition associated with platelet hyperreactivity in a subject in need thereof; and, monitoring the progression of a condition associated with platelet hyperreactivity in a subject diagnosed with the condition. Methods for determining the effect of an antiplatelet treatment on development of a condition associated with platelet hyperreactivity in a subject diagnosed with the condition, and identifying an antiplatelet treatment useful for slowing down the progression or treating a condition associated with platelet hyperreactivity in a subject diagnosed with the condition are also provided.